Medication diaries do not improve outcomes with highly active antiretroviral therapy in Kenyan children: a randomized clinical trial

Dalton C Wamalwa, Carey Farquhar, Elizabeth M Obimbo, Sara Selig, Dorothy A Mbori-Ngacha, Barbra A Richardson, Julie Overbaugh, Thaddeus Egondi, Irene Inwani, Grace John-Stewart, Dalton C Wamalwa, Carey Farquhar, Elizabeth M Obimbo, Sara Selig, Dorothy A Mbori-Ngacha, Barbra A Richardson, Julie Overbaugh, Thaddeus Egondi, Irene Inwani, Grace John-Stewart

Abstract

Background: As highly active antiretroviral therapy (HAART) becomes increasingly available to African children, it is important to evaluate simple and feasible methods of improving adherence in order to maximize benefits of therapy.

Methods: HIV-1-infected children initiating World Health Organization non-nucleoside reverse transcriptase-inhibitor-containing first-line HAART regimens were randomized to use medication diaries plus counselling, or counselling only (the control arm of the study). The diaries were completed daily by caregivers of children randomized to the diary and counselling arm for nine months. HIV-1 RNA, CD4+ T cell count, and z-scores for weight-for-age, height-for-age and weight-for-height were measured at a baseline and every three to six months. Self-reported adherence was assessed by questionnaires for nine months.

Results: Ninety HIV-1-infected children initiated HAART, and were followed for a median of 15 months (interquartile range: 2-21). Mean CD4 percentage was 17.2% in the diary arm versus 16.3% in the control arm at six months (p = 0.92), and 17.6% versus 18.9% at 15 months (p = 0.36). Virologic response with HIV-1 RNA of <100 copies/ml at nine months was similar between the two arms (50% for the diary arm and 36% for the control, p = 0.83). The weight-for-age, height-for-age and weight-for-height at three, nine and 15 months after HAART initiation were similar between arms. A trend towards lower self-reported adherence was observed in the diary versus the control arm (85% versus 92%, p = 0.08).

Conclusion: Medication diaries did not improve clinical and virologic response to HAART over a 15-month period. Children had good adherence and clinical response without additional interventions. This suggests that paediatric HAART with conventional counselling can be a successful approach. Further studies on targeted approaches for non-adherent children will be important.

Figures

Figure 1
Figure 1
Flow chart summarizing subject flow.
Figure 2
Figure 2
A – Self reported adherence by study arm; B – Weight-for-age Loess curves by study arm; C – CD4 count by study arm; D – Viral load Loess curves by study arm.

References

    1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;12(1):21–30.
    1. Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EV, Krogstad PA, Nachman S. Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;12(4):e6. doi: 10.1542/peds.109.4.e61.
    1. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. 2006.
    1. European Medicines Agency. Opinions for use of medicines outside the European Union. Aluvia H-C-764, European Public Assessment Report. 2008.
    1. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;12(8):682–9. doi: 10.1097/00006454-199908000-00006.
    1. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J. 2003;12(1):56–62. doi: 10.1097/00006454-200301000-00015.
    1. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;12(1):100–7. doi: 10.1086/430714.
    1. Reddi A, Leeper SC, Grobler AC, Geddes R, Rfance KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatrics. 2007;12:13. doi: 10.1186/1471-2431-7-13.
    1. Reddington C, Cohen J, Baldillo A, Toye M, Smith D, Kneut C, Demaria A, Bertolli J, Hsu HW. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2000;12(12):1148–53. doi: 10.1097/00006454-200012000-00005.
    1. Shankar G, Manaktala C, Verma M, Comparative Bioavailability study of a novel pediatric fixed dose dispersible tablet (FDDT) of lamivudine, stavudine and nevirapine versus individual marketed liquid formulations. XVI International AIDS Conference, Toronto, Canada; 2006. Oral abstract WEAB0304.
    1. Steele RG, Grauer D. Adherence to antiretroviral therapy for pediatric HIV infection: review of the literature and recommendations for research. Clin Child Fam Psychol Rev. 2003;12(1):17–30. doi: 10.1023/A:1022261905640.
    1. Stone V. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from clinical practice. Clin Infect Dis. 2001;12(6):865–72. doi: 10.1086/322698.
    1. Fogarty L, Debra R, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Pat Educ and Counseling. 2000;12:93–108. doi: 10.1016/S0738-3991(01)00219-1.
    1. Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, Boswell S. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;12(10):1151–62. doi: 10.1016/S0005-7967(00)00091-7.
    1. Tuldrà A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;12(Suppl 3):S154–7.
    1. Chesney M. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;12(suppl 2):S171–6. doi: 10.1086/313849.
    1. Wagner G. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and pill diaries. AIDS Patient Care STDs. 2002;12(12):599–608. doi: 10.1089/108729102761882134.
    1. Wagner G, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention? HIV Clin Trials. 2002;12(1):45–51. doi: 10.1310/XGXU-FUDK-A9QT-MPTF.
    1. Kenya Demographic Health Survey. Central Bureau of Statistics, Nairobi Kenya; 2003.
    1. Wamalwa D, Farquhar C, Obimbo E, Selig S, Mbori-Ngacha DA, Richardson BA, Overbaugh J, Emery S, Wariua G, Gichuhi C, Bosire R, John-Stewart Gl. Early response to highly active antiretroviral therapies among HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;12:311–317.
    1. Guidelines to antiretroviral therapy in Kenya. Ministry of Health, Nairobi, Kenya; 2005.
    1. Singh N, Squier C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;12:261–9. doi: 10.1080/09540129650125696.
    1. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C. The relationship between severity, health beliefs and medication adherence among HIV patients. AIDS Care. 2000;12:387–98. doi: 10.1080/09540120050123783.
    1. Treisman GJ. A behavioral approach for the promotion of adherence in complicated patient populations. Evolving HIV treatments: advances and the challenge of adherence, 37th Interscience Congress on Antimicrobial Agents and Chemotherapy Symposium, Toronto, Ontario; 1997.
    1. Wagner G, Rabkin JG. Measuring adherence: are missed doses reported more accurately than perfect adherence? AIDS Care. 2000;12(4):405–8. doi: 10.1080/09540120050123800.
    1. Farley J, Hines S, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment-keeping. J Acquir Immune Defic Syndr. 2003;12(2):211–8. doi: 10.1097/00126334-200306010-00016.
    1. Muller AD, Bode S, Myer L, Roux P, von Steinbüchel N. Electronic measurement of adherence to pediatric antiretroviral therapy in South Africa. Pediatr Infect Dis J. 2008;12(3):257–62. doi: 10.1097/INF.0b013e31815b1ad4.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj